NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock. The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account f ...

财务业绩与业务更新公告 - 公司将于2025年11月12日美国金融市场开盘前公布2025年第三季度财务业绩并提供项目更新[1] - 公司将于美国东部时间上午8:30举行电话会议和音频网络直播以讨论财务业绩和项目进展[1] 公司基本信息 - 公司为临床阶段生物技术公司专注于开发针对特定病原菌的新型天然和工程化噬菌体疗法[1][4] - 公司主要开发针对有害细菌的天然和工程化噬菌体鸡尾酒疗法及个性化噬菌体治疗方案用于治疗存在显著未满足需求的慢性疾病[4] - 公司通过其BOLT平台发现并验证专有细菌靶点并定制针对这些靶点的噬菌体组合[4]